Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sildenafil citrate, quantity: 35.1 mg (equivalent: sildenafil, qty 25 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; magnesium stearate; copovidone; microcrystalline cellulose; saccharin sodium; calcium hydrogen phosphate; croscarmellose sodium - noumed sildenafil is indicated for the treatment of erectile dysfunction in adult males. noumed sildenafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; povidone; hyprolose; silicon dioxide; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - cidala is indicated for the treatment of: - erectile dysfunction (ed) in adult males; - moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; silicon dioxide; croscarmellose sodium; lactose monohydrate; sodium lauryl sulfate; povidone; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - cidala is indicated for the treatment of: - erectile dysfunction (ed) in adult males; - moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; croscarmellose sodium; magnesium stearate; povidone; hyprolose; silicon dioxide; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - cidala is indicated for the treatment of: - erectile dysfunction (ed) in adult males; - moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: sodium lauryl sulfate; croscarmellose sodium; magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - tadalis is indicated in adults for the treatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 2.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; hyprolose; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; hyprolose; lactose monohydrate; croscarmellose sodium; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 10 mg - tablet - excipient ingredients: hyprolose; sodium lauryl sulfate; lactose monohydrate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itranox is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.